Hisamitsu Pharmaceutical Co., Inc. Q1 FY02/2011 Results

This presentation material contains information that constitutes forwardlooking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

Hisamitsu Pharmaceutical Co., Inc. June 30th, 2010

Patch and Care of People around the World

Consolidated PL

Alsamitsu

	① Q1 FY02/10	2 Q1 FY02/11	YoY	2-1			
Net sales	30,328	32,869	+8.4%	2,541			
CoGS	9,803	11,440	+16.7%	1,637			
as a % of sales	32.3%	34.8%		2.5%			
SG&A costs	13,373	14,746	+10.3%	1,373			
Advertising costs	2,720	2,542	△6.5%	-178			
R&D spending	2,093	2,725	+30.2%	632			
Operating profits	7,151	6,682	△6.6%	-469			
Recurring profits	7,388	7,464	+1.0%	76			
Net profits	4,396	6,085	+38.4%	1,689			
Unit: ¥1 million							

Patch and Care of People around the World

Aisamitsu

Summary of Profit and Loss

• Net sales : +2,541 (+8.4%)

- Noven : +2,191 Addition of Noven's sales
- Rx Business Div.: +1,684 Growth of sales of Mohrus Tape
- OTC Business Div.: Δ 1,644 Market reduction, Adjustment of trading stock
- International Div.: $\triangle 268$ Delay of shipment

• Operating profits : $\Delta 469 (\Delta 6.6\%)$

- $-\operatorname{CoGS}:\Delta1,637$
 - National Health Insurance price reduction
- Addition of costs of Noven
- SG&A expenses : Δ 1,373
 - Addition of SG&A expenses of Noven

• **Recurring profits : +76 (+1.0%)**

- Novogyne profit on equity method

• Net profits : +1,689 (+38.4%)

– Sales right permission fee

3

Aisamitsu

Patch and Care of People around the World

Sales results of major products

Unit: ¥1 million O1FY02/11 YoY FY02/11 Target YoY Mohrus Tapes 81,200 19,030 +9.5%+7.2% $\triangle 2.1\%$ 10,300 2.604 $\triangle 7.4\%$ Mohrus Paps Ethical drugs Naboal 2,200 +2.3%556 +0.4%1,000 Estrana 260 +12.1%+1.9%1,129 4,100 Vivelle-Dot 2,200 653 Noven therapeutics _ _ 237 Daytrana 1,300 _ _ Salonpas products 988 \triangle 36.0% 6,500 $\triangle 4.1\%$ drugs 3,900 $\triangle 17.4\%$ $\triangle 2.5\%$ Feitas products 781 $\triangle 34.4\%$ 3,600 $\triangle 3.0\%$ Salonship products 667 OTC Butena rock products 2,200 655 \triangle 36.5% +1.6%+11.3% $\triangle 24.6\%$ 1,850 Air Salonpas products 423

R&D Pipeline

Alsamitsu

Stage	Theme	Target	Dosage form	Characteristics	Next step
Approval	HFT-290 (Co-marketed with Kyowa Hakko Kirin)	Japan	Adhesive skin patch	Relief of cancer pain	-
Application being field	BTDS (In licensed from Mundipharma K.K.)	Japan	Adhesive skin patch	Relief of noncancer pain	Approval expected in FY10
Application being field	KPT-220 (Additional Indication of Mohrus®Tape)	Japan	Adhesive skin patch	Relief of pain and inflammation in acute symptom	Approval expected in FY12
РШ	HKT-500	US	Adhesive skin patch	Relief of joint pain, lower back pain and muscle pain	Under consideration
РШ	Mesafem	US	Oral	Vasomotor symptms (hot flashes)	Filed in FY11
РШ	HTU-520	Japan	Adhesive skin patch	Onychomycosis	Filed in FY12
PⅢ (in preparation)	HOB-294	Japan	Adhesive skin patch	Overactive bladder	Phase III in FY10
PIII (in preparation)	HFT-290 (Additional Indication of FENTOS®TAPE)	Japan	Adhesive skin patch	Relief of noncancer pain	Phase III in FY10

XYellow-highlighted parts are changes from the previous announcement made on Apr. 8.

Patch and Care of People around the World

disamitsu

5

Aiming at improving the QOL of people around the world

Q1 FY02/2011 Results

June 30th, 2010 Hisamitsu Pharmaceutical Co., Inc.


TT . T74	
Unit:¥1	million

7

	Q1FY02/11	YoY	FY02/11 Target	YoY
Rx Business	23,926	+7.6%	102,000	+6.5%
OTC Business	4,052	riangle 28.9%	20,700	+0.4%
Intl Business	687	riangle 28.1%	4,600	+3.4%
Total	28,667	riangle 0.8%	127,300	+5.4%

Patch and Care of People around the World

<Note to Editor> Trends of second-generation adhesive skin patch market (volume-basis)



<Note to Editor > Changes in shares of second-generation adhesive skin patches

